# Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients

> **NCT04888312** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Alligator Bioscience AB** · enrollment: 94 (actual)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma

## Interventions

- **BIOLOGICAL:** CD40 agonist mitazalimab in combination with chemotherapy

## Key facts

- **NCT ID:** NCT04888312
- **Lead sponsor:** Alligator Bioscience AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-17
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-06-30
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2025-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04888312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04888312, "Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04888312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*